昭和大学藤が丘病院における抗MRSA薬の適正使用へ向けたICTの取り組み

概要

論文の詳細を見る
The infection control team at Showa University Fujigaoka Hospital placed a formulary restriction on physicians' use of anti-methicillin resistant Staphylococcus aureus (MRSA) agents (vancomycin, arbekacin and teicoplanin) in January 2004. To evaluate the effect of this restriction, we investigated the changes in numbers of vials of anti-MRSA agents used between 1 year before and 1 year after the restriction was implemented, and in the numbers of new MRSA-positive inpatients (newly registered inpatients with MRSA infection or contamination). There was a significant decrease in monthly vial consumption for intravenous (iv) and oral vancomycins. This was accompanied by a 66% decrease in the cost of vancomycins used. However, there was no increase in the number of newly registered MRSA-positive inpatients over this period. There was also no significant change in monthly vial consumption for the newer anti-MRSA agents, arbekacin and teicoplanin, which was because the number of prescriptions of these drugs was much smaller than that for vancomycins. By hospital department, there was a remarkable decrease in iv and oral vancomycin usage in Gastroenterology and in the use of iv vancomycins in Chest Surgery. However, there was no significant decrease in newly registered MRSA-positive patients in these 2 departments. These findings suggest that such a formulary restriction contributes to ensuring the proper usage of anti-MRSA agents for inpatients with MRSA infections as well as to reducing medical costs.
日本医療薬学会の論文
2007-07-10

昭和大学藤が丘病院における抗MRSA薬の適正使用へ向けたICTの取り組み

スポンサーリンク

概要

著者

関連論文

スポンサーリンク